Myeloma Center

Bibliography

Found 43 results

] Title Type Year

Filters: Keyword is Multiple Myeloma [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosiñol L, Goranova-Marinova V, Mihaylov G et al.. 2016. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.. Blood. 128(9):1174-80.

B

Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. 2013. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.. Leukemia. 27(8):1707-14.

Boussi L, Niesvizky R. 2017. Advances in immunotherapy in multiple myeloma.. Curr Opin Oncol. 29(6):460-466.

Braunstein M, Niesvizky R. 2016. Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma.. Semin Oncol. 43(6):709-711.

C

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM et al.. 2017. IgM myeloma: A multicenter retrospective study of 134 patients.. Am J Hematol. 92(8):746-751.

D

Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R et al.. 2017. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.. Lancet Oncol. 18(10):1327-1337.

Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al.. 2017. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.

Dimopoulos MA, Terpos E, Niesvizky R. 2013. How lenalidomide is changing the treatment of patients with multiple myeloma.. Crit Rev Oncol Hematol. 88 Suppl 1:S23-35.

Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. 2015. Clinical characteristics of patients with relapsed multiple myeloma.. Cancer Treat Rev. 41(10):827-35.

Dimopoulos MA, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al.. 2017. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.. Blood Cancer J. 7(4):e554.

G

Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al.. 2010. Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.

Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA. 2014. IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.. Mod Pathol. 27(3):375-81.

J

Jhaveri KD, Niesvizky R. 2017. High-Cutoff Hemodialysis in Myeloma Cast Nephropathy.. JAMA. 318(21):2085-2086.

Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT et al.. 2016. Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.. Br J Haematol. 175(5):884-891.

K

Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM. 2013. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.. Br J Haematol. 163(4):478-86.

Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui A-M, Gupta N, Di Bacco A, Yu J et al.. 2014. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.. Blood. 124(7):1047-55.

Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, A Stewart K, Hari P, Roy V, Vescio R et al.. 2014. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.. Lancet Oncol. 15(13):1503-12.

Kwon D, Niesvizky R. 2013. Treatment of multiple myeloma with carfilzomib in patients with renal injury.. Clin Adv Hematol Oncol. 11(9):605-6.

M

Mark T, Jayabalan D, Coleman M, Pearse RN, Y Wang L, Lent R, Christos PJ, Lee JW, Agrawal YP, Matthew S et al.. 2008. Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.. Br J Haematol. 143(5):654-60.

Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D et al.. 2014. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.. Leuk Lymphoma. 55(12):2842-9.

Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, van Besien K, Shore T. 2013. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.. Biol Blood Marrow Transplant. 19(5):831-7.

Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, Larow A, Pearse RN, Harpel J, Shore T, Schuster MW et al.. 2008. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.. Biol Blood Marrow Transplant. 14(7):795-8.

Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T et al.. 2017. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.. Biol Blood Marrow Transplant. 23(6):930-937.

Mark TM, Coleman M, Niesvizky R. 2014. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.. Leuk Res. 38(5):517-24.

Mark T, Niesvizky R, Coleman M. 2009. Novel agents in myeloma: an exciting saga.. Cancer. 115(2):236-42.